- Study involved 171 TAVR patients, comparing NOACs and antiplatelet therapy.
- 30-day mortality: 33% (NOAC) vs 12% (antiplatelet).
- 1-year mortality: 41% (NOAC) vs 20% (antiplatelet).
- MACCE rates higher in NOAC group (22% at 30 days).
- NOACs showed increased use from 4% (2019) to 30% (2023) without improved outcomes.
- Major bleeding events were similar between groups.
- VKAs were not statistically compared due to small sample size.
- Larger trials needed for optimal antithrombotic strategies post-TAVR.
Source: Journal of Clinical Medicine
